labeling index. Additional markers in the eicosanoid pathway are also being analyzed. Results: To date, a total of 119 subject have been enrolled in the trial (the majority of these at the University of Colorado, n=82), with the investigators remaining blinded in terms of treatment groups. Fluorescent bronchoscopy was able to successfully identify areas of mild dysplasia or worse in the majority of patients (90/119, 76%). A total of 17 (14%) patients had normal bronchial epithelium at all biopsy sites. A wide range of endobronchial pathology has been observed in the biopsies, with average baseline histology being significantly elevated in current smokers. When biopsy sites are matched from the first and second bronchoscopies, changes in histologic grade have been observed, with more individual sites showing improvement (n=116) than progression (n=72). The subjects are all being scored on histologic outcomes and there have been subjects with partial responses, stable disease, and progression. In the subset of subjects with Ki-67 analysis (n=49), a significant increase in labeling index was associated with smoking status (current > former, p=0.006) and worsening histologic grade (p<0.001). Immunohistochemical analyses for other markers in the eicosanoid pathway (including COX-2, mPGES, PGIS) are currently in progress.
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Conclusions:
The iloprost chemoprevention trial continues to progress and has proven that our recruitment model can enrich for a population of subjects with endobronchial dysplasia. Results are still blinded. The treatment has been well tolerated and histologic improvement has been observed at specific biopsy sites in many of the subjects. Analysis of endobronchial biopsies for primary and secondary endpoints continues, and we are assessing different methodologies for evaluating clinical responses in chemoprevention trials (particularly those that could serve as a framework for current and future trials).
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Prevention Patients at high-risk for the development of lung cancer frequently harbor atypical airway epithelium (bronchial dysplasia). These lesions are believed to be precursors of invasive lung cancer, especially squamous type. However, previous studies of the natural history of these lesions have been limited by small numbers of specimens and short periods of follow-up. We performed an exhaustive analysis of all patients enrolled in Colorado SPORE bronchoscopy protocols who underwent multiple bronchoscopies to characterize the long-term outcome of these lesions. Methods: SPORE tissue bank records of histologic diagnosis, date of bronchoscopy and biopsy site for 121 patients (2,711 biopsies from 720 unique biopsy sites), who had between two and eight bronchoscopies over as many as 11 years were collected. Within subjects, biopsy sites from different bronchoscopies were matched and each site was classified into progression, persistent or regression groups. Each site was assigned an initial diagnosis according to WHO classification criteria. Progression, persistence and regression rankings were assigned according to whether the biopsy site showed change, or lack thereof, from the initial diagnosis to either of four diagnosis groups defined as: Non-dysplastic (normal, basal cell hyperplasia and squamous metaplasia without atypia); Dysplastic (mild, moderate and severe); Carcinoma-in-situ and Invasive carcinoma. In addition to progression score, individual bronchoscopies were scored for dysplasia index (DI), defined as the number of dysplastic biopsies (including CIS) divided by the total number of biopsies per bronchoscopy. Thirty patients with multiple brochoscopies had cancer diagnosed at some point during their enrollment. In analyses of relationships between bronchial histology and development of invasive cancer, an additional 28 patients with a single pre-carcinoma bronchoscopy were included. Results: High grade (HGD: moderate, severe dysplasia and CIS) bronchial lesions were more frequently persistent than low grade (LGD: mild) lesions (68.5% vs 43.7%, respectively; Chi-square <0.001). In addition, both initial and mean DI was higher in persistent versus non-persistent (regression) groups for HGD and LGD groups. Angiogenic squamous dysplasias (ASDs), a subset of dysplastic lesions, similarly showed increased persistence of HGD versus LGD lesions but additionally showed increased length of persistence in HGD-ASDs as compared non-ASD HGDs (25.5 vs. 17.1, respectiviely; p=0.024). A similar, non-significant trend toward increased length of persistence was seen for LGD-ASDs versus non-ASD LGDs. A trend toward increased persistence of HGD lesions in patients with all types of NSCLC versus no carcinoma patients (80% vs. 65%) was found, and this percentage was even higher, though still not statistically different, for the subset of patients with squamous cell carcinoma (85%). In addition, a trend toward increased mean DI in squamous cell carcinoma versus no carcinoma was seen (43% vs 31%). Conclusions: Analysis of high risk patients undergoing multiple bronchoscopies shows a relationship between persistence and degree of atypia in bronchial dysplasia. An increase in the length of persistence is associated with presence of ASD histology. An association between squamous cell carcinoma development and high DI and/or persistence of HGD is suggested. These data support the role of bronchial dysplasias as pre-malignant lesions in non-small cell lung cancer.
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